Pharmacological Approach of Type 2 Diabetes Mellitus

[1] ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., ... & Pekas, E. J. (2025). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care, 48.‏

[1] ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., ... & American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47.‏

[1] Lambrinou E, Hansen TB, Beulens JW. Lifestyle factors, self-management and patient empowerment in diabetes care. Eur J Prev Cardiol. 2019 Dec;26(2_suppl):55-63.

[1] Staimez LR, Weber MB, Gregg EW. The role of lifestyle change for prevention of cardiovascular disease in diabetes. Curr Atheroscler Rep. 2014 Dec;16(12):460.

[1] Powers MA, Bardsley JK, Cypress M, Funnell MM, Harms D, Hess-Fischl A, et al.. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care. (2020) 43:1636–49 10.2337/dci20-0023.

[1] Wang X, Qin LQ, Arafa A, Eshak ES, Hu Y, Dong JY. Smoking Cessation, Weight Gain, Cardiovascular Risk, and All-Cause Mortality: A Meta-analysis. Nicotine Tob Res. 2021 Nov 05;23(12):1987-1994.

[1] Riobó Serván P. [Diet recomendations in diabetes and obesity]. Nutr Hosp. 2018 Jun 12;35(Spec No4):109-115.

[1] Satpathy SV, Datta S, Upreti B. Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. J Pharm Bioallied Sci. 2016 Jul-Sep;8(3):2238. doi: 10.4103/0975-7406.175975.

[1] Das P, Das BP, Rauniar GP, Roy RK, Sharma SK. Drug utilization pattern and effectiveness analysis in diabetes mellitus at a tertiary care centre in eastern Nepal. Indian J Physiol Pharmacol. 2011 Jul-Sep;55(3):272–80.

[1] Xu Y, Yang Z, Lin H, Shen P, Wang H, Zhan S, et al. Long-term patterns of antidiabetic medications use in patients with type 2 diabetes. Med Sci Monit. 2018 Dec 2;24:8707–15. doi: 10.12659/MSM.913603.

[1] Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm. 2014 Jun;5(3):79–83. doi: 10.4103/0976-0105.139731.

[1] ADA “Standards of Care in Diabetes” 2024 Diabetes Care 2024;47(Suppl. 1):S158–S178 | https://doi.org/10.2337/dc24-S009

[1] Sowmya Swamy  Sahibzadi Mahrukh Noo  and  Roy O. Mathew Cardiovascular Disease in Diabetes and Chronic Kidney Disease J. Clin. Med. 2023, 12(22), 6984; https://doi.org/10.3390/jcm12226984

[1] Ji Chun,   Jodi Strong,  and Scott Urquhart Insulin Initiation and Titration in Patients With Type 2 Diabetes  Diabetes Spectr. 2019 May; 32(2): 104–111

[1] Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389–394.

[1] Obakiro SB, Kiyimb K, Napyo A, Knyike AM, Mayoka WJ, Nnassozi AG, et al. Appropriateness and affordability of prescriptions to diabetic patients attending a tertiary hospital in Eastern Uganda: A retrospective cross-sectional study. PLos One. 2021 Jan;16(1):e0245036. doi: 10.1371/journal.pone.0245036.

[1] Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clin Pharm. 2013 Sep;4(4):82–7. doi: 10.4103/0976-0105.121653.

[1] Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297–2307

[1] Cusi K, Orsak B, Bril F, Xuet al. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract 2020;170:108487

[1] Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2021;54:1150–1161

[1] Bizino MB, Jazet IM, de Heer P, et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia 2020;63:65–74

[1] Newsome PN, Buchholtz K, Cusi K, et al.; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113–1124

[1] Loomba R, Hartman ML, Lawitz EJ, et al.; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299–310

[1] Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393–406

[1] Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN Trial Team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679–690

[1]  Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 2011;19:2310–2315

[1] Abdul-Ghani M, Migahid O, Megahed A, DeFronzo RA, Al-Ozairi E, Jayyousi A. Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study. Diabetes Obes Metab 2020;22:2287–2294

[1] Lavynenko O, Abdul-Ghani M, Alatrach M, et al. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes Metab 2022;24:899–907.